Naturally acquired CD8+ cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. 1992

M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
Department of Defense Malaria Vaccine Program, Naval Medical Research Institute, Bethesda, MD 20889-5055.

In rodent malaria model systems, protective immunity induced by immunization with irradiated sporozoites is eliminated by in vivo depletion of CD8+ T cells, and adoptive transfer of CTL clones against the circumsporozoite protein protects against malaria. We recently demonstrated that volunteers immunized with irradiated Plasmodium falciparum sporozoites produce CTL against peptide 368-390 of the P. falciparum circumsporozoite protein. To determine whether natural exposure to malaria induced similar CTL, we studied 11 adult, male, life-long residents of a highly malarious area of Kenya, who were selected because their lymphocytes had been shown to proliferate after stimulation with peptides 361-380, 371-390, or 368-390 and because nine had been resistant to malaria in previous studies. In four of the 11 individuals there was peptide-specific, genetically restricted, CTL activity. In all four individuals, this activity was unaffected by depletion of CD4+ T cells. In three volunteers the activity was eliminated or reduced by depletion of CD8+ T cells; in the fourth volunteer the CD8+ T cell depletion was uninterpretable. This first demonstration of CD8+ T cell, genetically restricted, Ag-specific CTL against a malaria protein among individuals exposed to endemic malaria provides a foundation for studying the relationship between circulating CTL and resistance to malaria infection.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000953 Antigens, Protozoan Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered. Protozoan Antigens
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015800 Protozoan Proteins Proteins found in any species of protozoan. Proteins, Protozoan
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets

Related Publications

M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
April 1991, Proceedings of the National Academy of Sciences of the United States of America,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
December 1993, Infection and immunity,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
July 1988, Nature,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
August 1997, European journal of immunology,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
September 1986, The New England journal of medicine,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
February 1987, The New England journal of medicine,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
May 1995, Infection and immunity,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
August 2017, Antibodies (Basel, Switzerland),
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
July 1994, European journal of immunology,
M Sedegah, and B K Sim, and C Mason, and T Nutman, and A Malik, and C Roberts, and A Johnson, and J Ochola, and D Koech, and B Were
April 1994, Infection and immunity,
Copied contents to your clipboard!